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Abstract: In the past, polycystic ovary syndrome has been looked at primarily as an endocrine 
disorder. Studies now show that polycystic ovary syndrome is a metabolic, hormonal, and 
psychosocial disorder that impacts a patient’s quality of life. It is extremely important to holistically 
treat these patients early on to help them deal with the emotional stress that is often overlooked 
with polycystic ovary syndrome. Early diagnosis and long term management can help control 
polycystic ovary syndrome so that women can still live a healthy active life and avoid long-term 
complications such as metabolic syndrome and cardiovascular diseases.
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Background
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in 
women during their reproductive years1 with an estimated prevalence in 7–10 million 
American women.2 It affects 5%–10% of women in the developed world and is 
the most common endocrine disorder of women in their reproductive years3 PCOS 
is typically deﬁ  ned as hyperandrogenism associated with chronic anovulation in 
women without other underlying disease.3 At any age, PCOS can be devastating to 
women, especially during the reproductive years; PCOS is the leading cause of female 
infertility.4 Many women are often not immediately diagnosed with PCOS, and it is 
important for physicians to look for the hallmark signs of PCOS, such as menstrual 
cycle irregularity, hirsutism, infertility and a family history.4 Currently there is no 
consensus on diagnostic criteria for PCOS. The National Institutes of Health (NIH) 
consensus criteria consists of a minimal ﬁ  nding of: (i) menstrual irregularity due to 
olio- or anovulation, (ii) evidence of hyperandrogenism, whether clinical (hirsutism, 
acne, or male pattern balding) or biochemical (high serum androgen concentrations), 
(iii) exclusion of other causes of hyperandrogenism and menstrual irregularity (such as 
congenital adrenal hyperplasia, hyperprolactinemia, and androgen-secreting tumors). 
According to the Rotterdam consensus, a diagnosis of PCOS requires the presence 
of two of the following three conditions: (i) oligo- and/or anovulation, (ii) clini-
cal and/or biochemical signs of hyperandrogenism (acne, hirsutism, alopecia), and 
(iii) polycystic ovaries and the exclusion of other etiologies.5,6 The AES (Androgen 
Excess Society) taskforce determined that the original NIH criteria should be accepted 
with some modiﬁ  cations from the Rotterdam consensus (the only difference between 
the Rotterdam and AES diagnostic criteria is that according to Rotterdam criteria, a 
patient with polycystic ovaries and oligo- or anovulation would be diagnosed with 
PCOS, while under AES criteria they would not).7Drug, Healthcare and Patient Safety 2009:1 10
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It is important to note that outside of these criteria, 
women with PCOS often experience other conditions that 
can affect their short- and long-term physical and mental 
health. Decreased quality of life from mood disturbances, 
decreased sexual satisfaction, weight gain, acne vulgaris, and 
alopecia have all been documented.8 PCOS may represent one 
of the largest groups of women at high risk for the develop-
ment of early onset coronary heart disease.9 Although it is 
important to treat the short term disturbances for women, 
research shows that it is important to think about the future 
of women with PCOS, as many of them will develop meta-
bolic syndrome.10 Metabolic syndrome is a collection of 
cardiovascular disease risk factors associated with insulin 
resistance, dyslipidemia, hypertension, and central obesity.11 
This review highlights the current status regarding several 
important aspects of PCOS.
PCOS and quality of life in patients
Research shows that both physical health consequences and 
the emotional impact of PCOS have been ignored.12 PCOS 
and its inﬂ  uence on quality of life is an issue that needs to 
be taken seriously as this syndrome affects many women 
across the world. Measuring the quality of life of patients is 
often hard to do accurately. What one person may feel is a 
poorer quality of life may be very well suitable for another 
person. It is important to realize that although these scales 
and questionnaires have been well documented the informa-
tion taken from them is often subjective. How do we deﬁ  ne 
being satisﬁ  ed with our quality of life? For one woman it may 
be having a family and being a mother, for another woman 
it may be having a successful career, or for some it may be 
both. Standardized questionnaires such as the Polycystic 
Ovary Syndrome Health-Related Quality of Life Question-
naire (PCOSQ), the Short-Form Health Survey-36 (SF-36), 
Symptom Check List-90, and Visual Analog Scales (VAS), 
along with control groups, are often used to try to overcome 
these barriers.8,13 Simply asking a patient how they are feel-
ing may not prompt them to truly express the nature of their 
feelings. Patients were formerly treated primarily on their 
symptoms of PCOS, but current studies have shown that 
patients need to be treated more holistically, as PCOS can 
affect a woman’s mind, body, and her identity with herself 
as a woman.
Scales measuring quality of life are either generic or 
speciﬁ  c. Instruments that are illness speciﬁ  c provide more 
accurate information for that disease, while generic ques-
tionnaires such as the SF-36, although well validated, may 
lack in sensitivity as they are geared to measure health status 
across a wide variety of diseases.14,15 The SF-36 scale leaves 
out important detrimental issues linked to PCOS patients 
such as infertility and hirsutism, two items that can heavily 
impact a woman’s life.3 In 1998, the PCOSQ was created 
to speciﬁ  cally address these problems. This questionnaire 
focuses on the physical and emotional symptoms related 
to hirsutism, emotional impact of infertility, and physical 
symptoms associated with menstruation that can decrease a 
women’s overall quality of life.3
Although the SF-36 may lack sensitivity, the use of the 
questionnaire has been well validated, especially its use in 
conjunction with the PCOSQ. A recent study shows that the 
PCOSQ has reasonable internal reliability, good test-retest 
reliability, good concurrent and discriminant validity, and a 
reasonable factor analysis;14 making PCOSQ a useful and 
promising tool for measuring health-related quality of life 
(HRQoL) in PCOS patients.3,16 Based on the research shown 
by these scales, it is accurate to say that PCOS is indeed 
more than an endocrine disorder and that the effects of the 
diseases can have emotionally and psychological impact.14 
With this knowledge, it is justiﬁ  ed to take a further look into 
the exact ways in which PCOS can affect a woman’s total 
quality of life.
Sexual satisfaction
Although not all women (speciﬁ  cally adolescents) with 
PCOS may be sexually active, at some point in their lives 
they may be and sexual satisfaction may become important 
to them. Sexual satisfaction can play an important role, 
biologically and mentally, in a person’s life, as well as in 
relationships.
To assess sexual satisfaction, VAS are used, ranging from 
0–100 (with 0 being not at all affected, to 100 being very 
much affected). In one study, it was found that there was no 
statistical signiﬁ  cance in the frequency of sexual intercourse 
or thoughts of sex by either the PCOS group or the control 
group; what did prove signiﬁ  cant is that women with PCOS 
were shown to be signiﬁ  cantly less satisﬁ  ed with their sex 
life.13 Women with PCOS felt that their partners found them 
less attractive and felt that their partners were less satisﬁ  ed 
with their sexual relationship. Women with PCOS who 
were obese, or not obese, according to VAS results, both 
reported being less satisﬁ  ed with their sex life and both felt 
less sexually attractive.13
Studies evaluating sexual satisfaction can prove statisti-
cally signiﬁ  cant, but should be looked at only as a general 
conclusion. A study comparing healthy controls to women 
with PCOS showed no differences in sociodemographic Drug, Healthcare and Patient Safety 2009:1 11
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variables, ﬁ  nances, marriage, friends, and living conditions, 
leading researchers to believe that the differences in sexual 
satisfaction were due to the presence or absence of PCOS.13 It 
is important to take note that in this study, women in control 
groups did not rate their satisfaction at 100, showing that 
there may be other factors in women’s lives that determine 
if their sex life is satisfying and that PCOS may not be the 
root cause of dissatisfaction.
Infertility
PCOS is the most common endocrine disorder causing 
female fertility regardless of ethnicity.13,17,18 Approximately 
20% of couples in western society experience infertility.17 
Infertility occurs due to the ovulatory disturbances in PCOS,19 
and 100% of patients with PCOS suffer from ovulatory 
dysfunction according to the NIH 1990 criteria.20 Of this, 
75% of women with PCOS will experience infertility.21
For some women, having children is an important part 
of the female identity. Not only may her quality of life be 
affected, her partner or family may be affected; it should be 
noted that the extent of infertility on quality of life varies 
according to socio-cultural factors, traditions, and religious 
beliefs.18 Infertility is often associated with divorce, low 
social status, lowered self-esteem, altered self-perception, 
and job dissatisfaction.22,23 PCOS may also trigger infertility 
by causing stress and other psychosocial factors including 
distress, depression, anxiety, sexual problems, marital, 
and social maladjustment, lost of control, and lowered self 
esteem.17
Infertility does not simply become a concern to women 
with PCOS when they are trying to conceive, but recent 
studies have shown that it is a problem that even adolescent 
girls with PCOS are concerned about. If aware of infertility 
at a young age, women with PCOS may be inhibited 
emotionally and physically in establishing a long term 
relationship. In fact, one study reported a 3.4-fold incidence 
of concern using the Child Health Questionnaire-Child Self-
Report Form (CHQ-CF-87).
The PCOSQ questionnaire is often used to assess the 
impact of infertility on a woman with PCOS quality of life. 
Research has shown that patients with PCOS had a signiﬁ  cant 
negative impact on quality of life in many domains, including 
infertility, which had a 51% reduction in HRQoL compared to 
the control group.14 In this study, infertility had an alpha score 
above 0.90, indicating excellent reliability.14 It is reassuring 
to know that researchers have an accurate tool to measure 
the quality of life in PCOS patients, but now the problem is 
how to directly treat these issues.
One noteworthy study showed the importance of a Patient 
Information Questionnaire (PIQ).19 This questionnaire asked 
patients several questions, one of them being how they would 
rate the information given to them about how to handle 
fertility issues with PCOS. A majority of patients (48%) rated 
the information given poor, 31% fair, 18% good, 15% very 
good, 3% excellent in regards to fertility. Forty-seven percent 
of patients gained the most information from their physician, 
while 39% of information was gained from the Internet.19 
These numbers prove an important point, establishing a 
way to give patients better information is critical. It can 
be estimated that 50% of PCOS patients will actively seek 
infertility services at some point in their lifetime.24 Further 
studies need to be performed to assess whether or not these 
patients who seek infertility services were better informed 
about fertility and had better quality of life, because they felt 
more knowledgeable about the syndrome.
What has not been studied is to what extent does infertility 
impact the quality of life.25 Studies have shown that it can 
indeed decrease a woman’s quality of life, but more studies 
must be done to take into account different factors such as 
demographic features,18 previous treatment failure,26,27,28 and 
length of infertility.12,29 Another important point for consider-
ation is that infertility can be brought on by other triggers such 
as stress and depression. Of women with PCOS who experi-
ence infertility, the incidence of infertility in lean women with 
PCOS may be less,21 showing that weight may be a factor of 
infertility. Keeping these co-morbidities under control may 
be the key in preventing infertility in some women.
Psychological distress and emotional 
distress
It has been well documented that women with PCOS have 
higher levels of psychological distress.30 Symptoms of PCOS 
such as obesity, hirsutism and infertility have a strong inﬂ  uence 
on the psychosocial experience of women.30 Additionally, 
women with PCOS have been found to have higher levels of 
depression and overall psychological morbidity and decreased 
quality of life in overall health and sex.13,31
With diagnosis of any disorder, disease, or syndrome it is 
reasonable to say that a patient may have anxiety. The causes 
of this added anxiety in life is most attributable to hirsutism, 
irregular menses, and infertility.
One study analyzed the incidence of mental distress in 
women with untreated PCOS using self reported measures 
to characterize PCOS patients at risk for psychiatric disease 
with regards to sociodemographic and clinical characteristics 
and to assess the impact of emotional distress on quality Drug, Healthcare and Patient Safety 2009:1 12
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of life.32 To assess psychological distress, the German 
version of the SCL-90R was used to assess mental well 
being. This scale can be used for screening against cases 
of psychiatric/psychological illness. This ﬁ  ve-point scale 
assesses symptoms in nine areas: somatization, obsessive-
compulsive, interpersonal sensitivity, depression, anxiety, 
aggression, phobia, paranoid ideation, and psychoticism. The 
average of all 90 items gives a Global Severity Index (GSI) 
score that represents the overall level of distress in a patient.33 
Additionally, the Positive Symptom Distress Index (PSDI) 
was measured to depict the intensity of distress, while the 
Positive Symptom Total (PST) was taken to show the total 
number of distress-inducing symptoms.32
Of the 143 patients in this study, 15.4% had a possible 
psychological disorder based on GSI scores greater than 63 
(indicating possible mental disorder). As would be expected, 
women who showed mental disorders, scores greater than 
63 per the SCL, had a lower score on the SF-36, meaning 
they had a decreased quality of life. This data suggests 
that psychiatric illness may go undetected in patients with 
PCOS. This data does not, however, suggest that the degree 
of emotional distress and reduced quality of life can be 
accurately predicted.32 On the other hand, this data shows 
that just because a woman has PCOS and anxiety/distress, it 
does not mean that she necessarily has a mental or psychiatric 
disorder. This further justiﬁ  es the need for treatment of PCOS 
patients to be individualized.
Women with PCOS come from various backgrounds (cul-
ture, religion, socioeconomic status, and other comorbidities). 
Physicians and health care providers must ensure that they 
assess emotional distress on an individual basis. From here, 
providers can decide whether or not to further diagnosis 
or treatment by another health care specialist is required. 
Treating a PCOS patient should be multi-faceted and 
should involve a team of multiple medical experts. The 
extent to which physical symptoms have been correlated to 
psychological and emotional distress is limited and needs 
to be further explored. Although studies are scarce in this 
dimension, a majority of experts acknowledge that the psy-
chosocial burden in women with PCOS cannot be ignored, 
and should be treated as a secondary symptom.17
Hirsutism
Hirsutism is often cited by patients as being one of the most 
disturbing aspects of PCOS,34 causing marked psychological 
stress.35 Hirsutism is the excessive hair growth in women 
following a male distribution pattern and can be evaluated 
through the Ferriman–Gallwey (FG) map scoring system. 
The degree of hirsutism found in patients determined by the 
FG score is inﬂ  uenced not only by androgen levels but is also 
linked to insulin levels and insulin resistance.36,37 Therefore 
lifestyle changes may have a positive effect on the speed of 
hair growth, which can help improve QOL. Facial hair in 
women has been shown to cause distress.38 Not only does 
the distress stem from the hair growth itself, but from the 
considerable amount of time and energy to try to keep the 
condition hidden.35,39,40 Women with PCOS who experience 
hirsutism have often expressed that they feel “unfeminine,” 
“freakish,” “weird,” and “different.”41 This study interviewed 
30 women with PCOS to ﬁ  nd out that the three most trouble-
some problems for them were excess hair growth, irregular 
menses, and infertility. All three of these characteristics 
were areas women described as what they deﬁ  ned as being 
feminine and, as a result of PCOS, they felt robbed of their 
female identity. In this interview, patients were asked to 
describe their diagnosis with PCOS, symptoms they had and 
how they dealt with them, and also how they felt PCOS had 
inﬂ  uenced their lives.41
The feedback from these 30 women were eye opening 
to the difﬁ  culties that a women with hirsutism experiences. 
One interviewee commented, “A woman with a beard is, you 
know terrible. I think the hair is the worst thing because it’s 
visible and it’s so abnormal.” Facial hair was a problem for 
90% of patients who participated in the PCOSQ development 
group.16 From these numbers it is clear that this is an 
important issue for women with PCOS. Not only is exces-
sive hair a concern, but the desire to get help has also been 
posed as a difﬁ  culty. Women expressed that they felt health 
care professionals did not take their symptoms seriously.41 
Having a close and trusting relationship is crucial in the 
management of any syndrome and PCOS should not be any 
different. Health care providers need to make sure that their 
patients fully understand PCOS, and they are compassionate 
about the concerns patients may have.
Another study found that more severe hirsutism was asso-
ciated with lower SF-36 scale scores for pain, general health 
perception, the physical sum scale, as well as decreased 
sexual self-worth and sexual satisfaction.8 Simultaneously, 
a study in Germany found that there could be no correlation 
between hirsutism and psychosocial distress or in areas of 
quality of life concerning emotional and social functioning.8 
This study brings into question: Are there differences 
between hirsutism in different cultures? Limitations to this 
study also include the use of generic instruments. Researchers 
acknowledge that a disease speciﬁ  c instrument may be more 
sensitive to changes.8 Due to the limited amount of research Drug, Healthcare and Patient Safety 2009:1 13
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in this area, health care professionals need to pay attention to 
the psychosocial dimension of PCOS on an individual basis, 
as it may not be possible to predict based on the presence or 
absence of symptoms such as hirsutism.8
Metabolic syndrome and coronary 
artery disease
Cardiovascular disease remains the leading cause of morbidity 
and mortality in women.42 Metabolic syndrome is a combi-
nation of cardiovascular disease risk factors associated with 
glucose intolerance, dyslipidemia, hypertension, and central 
obesity.11 Most associate PCOS with its ovulatory detriments, 
but research has shown growing concern in the area of meta-
bolic syndrome and coronary artery disease in patients with 
PCOS.43,44 In fact, regardless of the diagnostic criteria used 
(NIH, Rotterdam or AES), fertile women with PCOS show 
an increase in prevalence of metabolic syndrome and hyper-
insulinism compared with the healthy population;45 indicating 
the importance of metabolic parameters and insulin resistance 
in PCOS. As we know, PCOS can have debilitating aspects 
that affects a woman’s day to day life. It is very important to 
treat the symptoms of PCOS such as hirsutism, infertility, and 
menstrual irregularity, but it is wise to think about the future 
of these patients and what other complications may stem from 
PCOS that affect the patient population. Complications such 
as CAD, endometrial carcinoma, metabolic syndrome, sleep 
apnea, nonalcoholic steatohepatosis, depression, diabetes 
and breast cancer are some important things to keep in mind 
when facing a woman with PCOS.
It has been estimated that myocardial infarction is seven 
times more likely in patients with PCOS.46 It has also been 
observed that there is a 50% greater risk of myocardial 
infarction or fatal CHD among women with a history or 
irregular menstrual cycles at ages 20–35 years compared with 
a control group.47 PCOS can cause irregular menstrual cycles, 
so women with PCOS are in the population of women at higher 
risk for myocardial infarction.47 Additionally, cardiac cath-
eterization studies have shown more extensive coronary artery 
disease in patients with PCOS compared to that of healthy 
control groups.48 These ﬁ  ndings are alarming, and justify the 
need for further investigation into the several dimensions 
of PCOS. Not only have several coronary risk factors been 
well documented in women with PCOS, but elevated rates 
of obesity,46,49,50 central obesity,49 glucose intolerance11,51 and 
increased blood pressure49 have been found.
A 2006 study found that of 78 adolescents with PCOS 
had a substantially higher risk of developing metabolic 
syndrome and hypertension compared with the general 
female adolescent population; this information was obtained 
from the third National Health and Nutrition Examination 
Survey (NHANES III) using the Cook criteria (37% vs 5%) 
and the de Ferranti criteria (47% vs 13%).52,53 This study also 
had other interesting ﬁ  ndings; none of the girls of normal 
body mass index had metabolic syndrome, whereas 11% of 
overweight and 63% of obese girls with PCOS had metabolic 
syndrome compared with 0 and 32% of the NHANES III 
population.11 In total, of the 78 adolescent girls with PCOS, 
63% of them had the complete data for diagnosis of meta-
bolic syndrome.
In general, studies support the trend that PCOS women are 
at higher risk for metabolic syndrome and have an increased 
risk for cardiovascular diseases even with small sample sizes. 
It should be taken into account that different studies use 
different criteria, often not making the populations between 
studies homogenous.42 Additionally, many studies take place 
in different areas of the world making it hard to generalize 
information to ﬁ  t all women with PCOS. For example, it 
was found that the prevalence of metabolic syndrome in 
PCOS patients appears to be much lower in Italy than in 
the United States.54 Race is also an important factor when 
performing these studies, and not all studies have included 
this information. A 2006 study showed that among women 
with PCOS, whites, blacks, and Hispanics were more likely 
to be obese; Asians and Hispanics were more likely to have 
diabetes; and blacks were more likely to have hypertension, 
while Hispanics were less likely to have hypertension.55 
It is not accurate to say that current literature in regards 
to metabolic syndrome in PCOS has not provided useful 
information, but continued studies are needed. Studies such 
as one with large sample size comparing women not just 
to control groups but also to women of different cultures, 
is needed to help make suggestions to the public on this 
disorder.
Research has shown that keeping PCOS under control 
and preventing components of metabolic syndrome will 
work if the physician and patient work together. Physicians 
must provide early intervention and long-term monitoring 
for women with PCOS and need to continue this lifelong 
monitoring; these patients are at increased risk for 
complications as they age, as body mass index increases, 
and in the presence of diabetes.56,57 Early treatment is the key 
with these patients, no matter their age at diagnosis. Even 
young, obese adolescents with PCOS have been found to 
have a high prevalence of early endocrine, metabolic, and 
cardiovascular characteristics.2 Many early symptoms of 
coronary artery diseases are silent, making it important to Drug, Healthcare and Patient Safety 2009:1 14
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keep up with routine lab tests and monitoring. Patients must 
also take responsibility in their health care and make lifestyle 
modiﬁ  cations such as diet, exercise, and smoking cessation 
to help prevent complications of metabolic syndrome.57
Obesity and diabetes have increased dramatically worldwide 
during the last decade.56 Losing weight, if overweight, is a crit-
ical part of a woman’s health, especially those with PCOS.58 
Not only does obesity act as a risk factor for other health prob-
lems, it has been shown that obesity and weight gain are likely 
to lead to loss of self-esteem and poor body image, resulting in 
a decreased quality of life and psychological morbidity.19 If a 
woman is overweight, oral glucose tests should be performed 
by the patient’s physician. It has been found that greater than 
25% of obese women with PCOS will develop impaired 
glucose or type 2 diabetes.57 For physicians, it is important 
to stress to patients with PCOS that the best therapy for them 
is weight loss; hyperinsulinemia and hyperandrogenism can 
be reduced with weight loss.57 It has been well documented 
that insulin resistance is responsible for the high androgen 
concentration in women with PCOS.59 Not only could losing 
weight help women prevent metabolic complications, but it 
can aid in decreasing their symptoms of hyperandrogenism, 
such as excessive hair growth and acne, and possibly increase 
their quality of life. It is also important to remember that in 
PCOS patients’ lipid metabolism is often impaired. In patients 
who are obese, it has been shown that there is a speciﬁ  c reduc-
tion in high-density lipoprotein lipid formation, therefore a 
reduced capacity for cholesterol elimination.58 One study has 
shown that there are some metabolic features of PCOS that 
are present in daughters of PCOS women before the onset of 
hyperandrogenism, so not only is it important to care for their 
own bodies, but also for the future of their daughters.60,61
Conclusion
PCOS is not just an endocrine disorder, but a combination 
of metabolic and psychosocial detriments. Not addressing 
all the aspects of PCOS, such as depression, may delay 
the treatment of the “primary” issues such as fertility and 
hyperandrogenism. While further research needs to be 
conducted with larger sample sizes, current research does 
suggest a decreased quality of life in this population. It 
is evident that a universally accepted diagnostic criterion 
needs to be implemented by researchers and health care 
professionals. The longer proper treatment is delayed, 
chances are increased of the patient developing other health 
issues such as metabolic syndrome and cardiovascular 
disease. Treating the patient holistically seems like a very 
simple answer to a large problem; this will only happen if 
health care professionals are committed to increasing patient 
education, and helping patients ﬁ  nd the proper treatment for 
all aspects of this disease.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
 1. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on 
the management of polycystic ovary syndrome. Pharmacol Rep. 
2006;58:614–625.
  2.  Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. 
Young obese women with polycystic ovary syndrome have evidence 
of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007;
92:4609–4614.
  3.  Jones GL, Benes K, Clark TL, et al. The Polycystic Ovary Syndrome 
Health-Related Quality of Life Questionnaire (PCOSQ): a validation. 
Hum Reprod. 2004;19:371–377.
  4.  Torpy JM, Lynm C, Glass RM. JAMA patient page. Polycystic ovary 
syndrome. JAMA. 2007;297:554.
  5.  Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, 
Fauser BC. PCOS according to the Rotterdam consensus criteria: 
Change in prevalence among WHO-II anovulation and association 
with metabolic factors. BJOG. 2006;113:1210–1217.
  6.  Stankiewicz M, Norman R. Diagnosis and management of polycystic 
ovary syndrome: a practical guide. Drugs. 2006;66:903–912.
  7.  Azziz R, Carmina E, Dewailly D, et al. Criteria for deﬁ  ning polycystic 
ovary syndrome as a predominantly hyperandrogenic syndrome: 
an androgen excess society guideline. J Clin Endocrinol Metab. 
2006;91:4237–4245.
  8.  Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates 
of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol. 
2005;153:853–860.
 9. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for 
association between polycystic ovary syndrome and premature carotid 
atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 
2000;20:2414–2421.
10. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of 
metabolic syndrome frequency and premature carotid atherosclerosis 
in young women with polycystic ovary syndrome. Hum Reprod. 
2005;20:2409–2413.
11. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic 
ovary syndrome have an increased risk of the metabolic syndrome 
associated with increasing androgen levels independent of obesity and 
insulin resistance. J Clin Endocrinol Metab. 2006;91:492–497.
12. McCook JG, Reame NE, Thatcher SS. Health-related quality of life 
issues in women with polycystic ovary syndrome. J Obstet Gynecol 
Neonatal Nurs. 2005;34:12–20.
13.  Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial 
well-being, and sexual satisfaction in women with polycystic ovary 
syndrome. J Clin Endocrinol Metab. 2003;88:5801–5807.
14.  Coffey S, Bano G, Mason HD. Health-related quality of life in women 
with polycystic ovary syndrome: a comparison with the general population 
using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the 
Short Form-36 (SF–36). Gynecol Endocrinol. 2006;22:80–86.
15.  Streiner DL, Norman G. Health Measurement Scales: A practical guide 
to their development and use. 2nd ed. Oxford, UK: Oxford University 
Press; 2000.
16.  Cronin L, Guyatt G, Grifﬁ  th L, et al. Development of a health–related 
quality-of-life questionnaire (PCOSQ) for women with polycystic ovary 
syndrome (PCOS). J Clin Endocrinol Metab. 1998;83:1976–1987.
17.  Eggers S, Kirchengast S. The polycystic ovary syndrome – a medical 
condition but also an important psychosocial problem. Coll Antropol. 
2001;25:673–685.Drug, Healthcare and Patient Safety 2009:1 15
PCOS: More than an endocrine disorder
18.  Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused 
by PCOS – health-related quality of life among Austrian and Moslem 
immigrant women in Austria. Hum Reprod. 2004;19:2251–2257.
19. Ching HL, Burke V, Stuckey BG. Quality of life and psychological 
morbidity in women with polycystic ovary syndrome: body mass index, 
age and the provision of patient information are signiﬁ  cant modiﬁ  ers. 
Clin Endocrinol (Oxf). 2007;66:373–379.
20.  Homburg R. What is polycystic ovarian syndrome? A proposal for a 
consensus on the deﬁ  nition and diagnosis of polycystic ovarian syndrome. 
Hum Reprod. 2002;17:2495–2499.
21. Goldzieher JW, Axelrod LR. Clinical and biochemical features of 
polycystic ovarian disease. Fertil Steril. 1963;14:631–653.
22.  Paulson JD, Haarmann BS, Salerno RL, Asmar P. An investigation of 
the relationship between emotional maladjustment and infertility. Fertil 
Steril. 1988;49:258–262.
23.  Downey J, Yingling S, McKinney M, Husami N, Jewelewicz R, 
Maidman J. Mood disorders, psychiatric symptoms and distress in women 
presenting for infertility evaluation. Fertil Steril. 1989;52:425–432.
24.  Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-
related economic burden of the polycystic ovary syndrome during the 
reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–4658.
25.  Monga M, Alexandrescu B, Katz SE, Stein M, Ganiats T. Impact of 
infertility on quality of life, marital adjustment, and sexual function. 
Urology. 2004;63:126–130.
26.  Boivin J, Takefman JE, Tulandi T, Brender W. Reactions to infertility 
based on extent of treatment failure. Fertil Steril. 1995;63:801–807.
27.  Guerra D, Llobera A, Veiga A, Barri PN. Psychiatric morbidity in couples 
attending a fertility service. Hum Reprod. 1998;13:1733–1736.
28.  Oddens BJ, den Tonkelaar I, Nieuwenhuyse H. Psychosocial 
experiences in women facing fertility problems – a comparative survey. 
Hum Reprod. 1999;14:255–261.
29.  Fekkes M, Buitendijk SE, Verrips GH, et al. Health-related quality of 
life in relation to gender and age in couples planning IVF treatment. 
Hum Reprod. 2003;18:1536–1543.
30.  Esler DM, Travers CA, Guttikonda K, Dixon A, Lewis PR. The 
psychosocial experience of women with PCOS – a case control study. 
Aust Fam Physician. 2007;36:965–967.
31.  Weiner CL, Primeau M, Ehrmann DA. Androgens and mood 
dysfunction in women: comparison of women with polycystic ovarian 
syndrome to healthy controls. Psychosom Med. 2004;66:356–362.
32. Elsenbruch S, Benson S, Hahn S, et al. Determinants of emotional 
distress in women with polycystic ovary syndrome. Hum Reprod. 
2006;21:1092–1099.
33. Derogatis  LR.  SCL-90-R: Administration, Scoring and Procedures – 
Manual II. Baltimore, MD: Clinical Psychometric Research; 1983.
34.  Coffey S, Mason H. The effect of polycystic ovary syndrome on health-
related quality of life. Gynecol Endocrinol. 2003;17:379–386.
35.  Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life 
of hirsute women. Postgrad Med J. 1993;69:186–189.
36. Amato MC, Galluzzo A, Merlino S, et al. Lower insulin sensitivity 
differentiates hirsute from non-hirsute Sicillian women with polycystic 
ovary syndrome. Eur J Endocrinol. 2006;155:859–865.
37.  Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent 
of androgen levels, is an important determinant of the severity of 
hirsutism in PCOS. Fertil Steril. 2008;Aug 21 [Epub ahead of print].
38.  Rabinowitz S, Cohen R, Le Roith D. Anxiety and hirsutism. Psychol 
Rep. 1983;53(3 Pt 1):827–830.
39.  Conn JJ, Jacobs HS. Managing hirsutism in gynaecological practice. 
Br J Obstet Gynaecol. 1998;105:687–696.
40. Lanigan S, Kwan C, Dykes P, Gonzales M. Quality of life studies 
in hirsute women receiving ruby laser treatment. Br J Dermatol. 
2000;143(Suppl 57):50.
41.  Kitzinger C, Willmott J. ‘The thief of womanhood’: women’s experience 
of polycystic ovarian syndrome. Soc Sci Med. 2002;54:349–361.
42. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a 
premature association? Endocr Rev. 2003;24:302–312.
43.  Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and 
characteristics of the metabolic syndrome in women with polycystic 
ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–1935.
44.  Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. 
Prevalence and predictors of the metabolic syndrome in women with 
polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53.
45.  Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C. 
The evaluation of metabolic parameters and insulin sensitivity for 
a more robust diagnosis of the polycystic ovary syndrome. Clin 
Endocrinol (Oxf). 2008;69(1):52–60.
46.  Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic 
ovary syndrome and risk for myocardial infarction. Evaluated from a 
risk factor model based on a prospective population study of women. 
Acta Obstet Gynecol Scand. 1992;71:599–604.
47. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity 
and risk for future cardiovascular disease. J Clin Endocrinol Metab. 
2002;87:2013–2017.
48. Birdsall  MA,  Farquhar CM, White HD. Association between polycystic 
ovaries and extent of coronary artery disease in women having cardiac 
catheterisation. Ann Intern Med. 1997;126:32–35.
49.  Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors 
in women with polycystic ovary syndrome. Arterioscler Thromb Vasc 
Biol. 1995;15:821–826.
50.  Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease 
in women with polycystic ovary syndrome at long-term follow-up: a 
retrospective cohort study. Clin Endocrinol (Oxf). 2000;52:595–600.
51.  Montague CT, O’Rahilly S. The perils of portliness: causes and con-
sequences of visceral adiposity. Diabetes. 2000;49:883–888.
52.  Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence 
of a metabolic syndrome phenotype in adolescents:ﬁ  ndings from the 
thrid National Health and Nutrition Examination Survey, 1988–1994. 
Arch Pediatr Adolesc Med. 2003;157:821–827.
53.  de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, 
Rifai N. Prevalence of the metabolic syndrome in American adolescents: 
ﬁ  ndings from the Third National Health and Nutrition Examination 
Survey. Circulation. 2004;110:2494–2497.
54.  Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic 
syndrome in polycystic ovary syndrome (PCOS): lower prevalence 
in southern Italy than in the USA and the inﬂ  uence of criteria for the 
diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–145.
55. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. 
Epidemiology and adverse cardiovascular risk proﬁ  le of diagnosed 
polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91: 
1357–1363.
56. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the 
metabolic syndrome in a Danish population of women with previous 
gestational diabetes mellitus is three-fold higher than in the general 
population. J Clin Endocrinol Metab. 2005;90:4004–4010.
57. Vignesh JP, Mohan V. Polycystic ovary syndrome: a component of 
metabolic syndrome? J Postgrad Med. 2007;53:128–134.
58. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of 
high density lipoproteins in women with the polycystic ovary syndrome. 
J Clin Endocrinol Metab. 1997;82:3389–3394.
59.  Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy 
on hyperandrogenism in women with polycystic ovarian syndrome. 
Gynecol Endocrinol. 2003;17:51–56.
60. Leibel  NI, Baumann EE, Kocherginsky M, Rosenﬁ  eld RL. Relationship 
of adolescent polycystic ovary syndrome to parental metabolic 
syndrome. J Clin Endocrinol Metab. 2006;91:1275–1283.
61. Sir-Petermann T, Maliqueo M, Codner E, et al. Early metabolic 
derangements in daughters of women with polycystic ovary syndrome. 
J Clin Endocrinol Metab. 2007;92:4637–4642.